Marvel Biosciences Corp (TSE:MRVL)
:MRVL
MRVL Stock Chart & Stats
C$0.14
-C$0.01(-6.45%)
At close: 4:00 PM EST
C$0.14
-C$0.01(-6.45%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.40
Previous CloseN/A
Volume5.00K
Average Volume (3M)89.38K
Market Cap
C$9.57M
Enterprise ValueC$11.90M
Total Cash (Recent Filing)C$274.17K
Total Debt (Recent Filing)C$2.31M
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Jun 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding58,004,482
10 Day Avg. Volume75,294
30 Day Avg. Volume89,378
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash BurnOperating cash burn has improved versus prior years, with TTM operating cash flow around -$1.47M. That trend reduces immediate financing pressure, extends runway versus prior periods, and signals more disciplined capital deployment—supporting near-term sustainability for an early-stage biotech.
Narrowing Net LossesTTM net loss narrowed to roughly $2.1M from larger losses in 2022–2023, indicating progress on cost control or program prioritization. For an early-stage biotech, a consistent reduction in losses suggests improved operational discipline and a stronger platform for funding future development.
Lean Operating StructureA very small headcount (5 employees) keeps fixed costs low and allows management to allocate limited capital to core R&D activities. That lean model reduces cash burn and gives the company flexibility to pivot programs without large structural overhead, helpful in a pre-revenue stage.
Bears Say
Pre-revenue Business ModelThe company remains pre-revenue with negative gross profit and ongoing operating losses, meaning no internal cash generation from products. This structural reliance on external financing increases dilution risk and leaves long-term viability contingent on successful clinical progress or financing events.
Negative Shareholder EquityNegative shareholders' equity (~-$3.9M TTM) alongside meaningful debt (~$2.31M) signals accumulated losses have eroded the capital base. This constrains financial flexibility, raises refinancing and covenant risks, and increases the likelihood of future dilution to support operations or development programs.
Very Small Asset BaseWith total assets of roughly $0.32M TTM, the company has limited tangible resources to support growth or secure additional debt. A minimal asset base reduces collateral options, complicates scalability of R&D programs, and heightens dependence on equity financings and external partnerships.
Marvel Biosciences Corp News
MRVL FAQ
What was Marvel Biosciences Corp’s price range in the past 12 months?
Marvel Biosciences Corp lowest stock price was C$0.07 and its highest was C$0.40 in the past 12 months.
What is Marvel Biosciences Corp’s market cap?
Marvel Biosciences Corp’s market cap is C$9.57M.
When is Marvel Biosciences Corp’s upcoming earnings report date?
Marvel Biosciences Corp’s upcoming earnings report date is Jun 23, 2026 which is in 75 days.
How were Marvel Biosciences Corp’s earnings last quarter?
Marvel Biosciences Corp released its earnings results on Mar 31, 2026. The company reported -C$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.005.
Is Marvel Biosciences Corp overvalued?
According to Wall Street analysts Marvel Biosciences Corp’s price is currently Overvalued.
Does Marvel Biosciences Corp pay dividends?
Marvel Biosciences Corp does not currently pay dividends.
What is Marvel Biosciences Corp’s EPS estimate?
Marvel Biosciences Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marvel Biosciences Corp have?
Marvel Biosciences Corp has 58,004,482 shares outstanding.
What happened to Marvel Biosciences Corp’s price movement after its last earnings report?
Marvel Biosciences Corp reported an EPS of -C$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of Marvel Biosciences Corp?
Currently, no hedge funds are holding shares in TSE:MRVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marvel Biosciences Corp
Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002) and MB-204 an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.
Technical Analysis
BetterLife Pharma
―
―
Entheon Biomedical
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Options Prices
Currently, No data available
---